Drug-resistant TB: latest news

Drug-resistant TB resources

Drug-resistant TB features

Drug-resistant TB news from aidsmap

More news

Drug-resistant TB news selected from other sources

  • USAID announces new partnerships to combat MDR-TB

    At last week’s launch of the National Action Plan for Combating Multidrug-Resistant Tuberculosis, the U.S. Agency for International Development announced expanded partnerships with Janssen, the maker of bedaquiline, the first tuberculosis drug to be produced since the 1950s, and Cepheid, maker of the GeneXpert rapid diagnostic test for drug-resistant tuberculosis.

    13 January 2016 | Science Speaks
  • Did poor bedside manner cause the rise of multidrug-resistant TB?

    A 2012 article in the Journal of Tuberculosis and Lung Disease noted that the powerfully negative connotation of words such as “defaulter” and “suspect” placed blame for the disease and responsibility for adverse treatment outcomes on just one side: people with TB. Is it any wonder that patients fail to complete their treatment or don’t return for checkups if they are made to feel guilty?

    12 January 2016 | Devex
  • TAG’s Response to the U.S. Action Plan for Combating Multidrug Resistant Tuberculosis

    Treatment Action Group (TAG) welcomes the release of the Obama Administration’s National Action Plan for Combating Multidrug-Resistant Tuberculosis. Strengthening the domestic and global and research efforts to address multidrug-resistant tuberculosis (MDR-TB) are critical to ending the suffering this preventable, curable disease needlessly causes. However, the targets set forth in this plan are not ambitious enough to effectively stop the spread of MDR-TB.

    11 January 2016 | Treatment Action Group
  • First new TB drugs in half a century reach just 2% of people who need them

    MSF calls for companies to make new drugs to treat drug-resistant TB available and affordable.

    04 December 2015 | MSF
  • New cohort study shows promise of dramatically shorter treatment option for multidrug - resistant TB

    New findings from clinical studies presented at the 46th Union World Conference on Lung Health show promise for a shorter, 9 -month treatment course for MDR-TB. The standard treatment length recommended by the World Health Organization requires 24 months of treatment.

    03 December 2015 | 46th Union World Conference on Lung Health
  • New survey shows outdated TB policies and practices risking further spread of drug-resistant TB

    Urgent phase-out needed for outdated policies of mandatory hospitalisation, re-treatment regimens that contribute to drug resistance, and sub-optimal diagnosis.

    03 December 2015 | MSF
  • Bulk of world’s MDR-TB cases undiagnosed – WHO

    The world may be losing the war against the rise of drug-resistant tuberculosis (TB) as the bulk of patients with multidrug-resistant TB go undiagnosed, according to the World Health Organisation’s (WHO) latest TB report.

    28 October 2015 | Health-E News
  • Nonprofit Gets Back Drug and Reverses 18-Fold Increase in Price

    A nonprofit in Indiana has dropped the price of a drug for multi-drug resistant tuberculosis roughly 90% after re-acquiring rights to the medicine from Rodelis Therapeutics, the latest sign of a growing outcry over skyrocketing costs for rare disease treatments.

    22 September 2015 | Bloomberg
  • NHS England commissions first new TB drugs in 50 years

    NHS England has published a new Clinical Commissioning Policy making Janssen’s Sirturo and Otsuka’s Deltyba routinely available on the National Health Service for the treatment of pulmonary multi-drug resistant tuberculosis, offering patients easier access to the first novel therapies in nearly 50 years.

    25 August 2015 | Pharma Times
  • Medicines Patent Pool At 5 Years: Promises Kept, Changes Ahead – An Interview With Greg Perry

    The Medicines Patent Pool in Geneva is celebrating five years of existence this month. MPP Executive Director Greg Perry sat down with Intellectual Property Watch Catherine Saez to describe progress made since its inception, the success of its licensing agreement model, and plans for the future, including a possible extension to other diseases such as tuberculosis and hepatitis C.

    04 August 2015 | Intellectual Property Watch
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also